Why Are Midlife Women Being Ignored in GLP-1 Research?

Women in midlife experience significant hormonal shifts — declining estrogen, progesterone, and testosterone — that alter metabolism, increase central fat storage, and make traditional weight loss strategies less effective.

Many women in this age group have tried every approach and find that GLP-1s finally give them traction.

However, this demographic is also the most underrepresented in clinical research on these medications, meaning much of what we know about GLP-1 efficacy is based on studies that did not adequately include them.

When women — particularly postmenopausal women — stop GLP-1 medications without adequate lifestyle support in place, research suggests they often regain weight predominantly as fat rather than muscle.

This can leave them in a worse metabolic position than before starting the medication.

This is not a personal failure. It is a physiological response that underscores why sustainable habit-building — particularly resistance training and adequate protein intake — must run alongside any medication protocol, not after it.

The black box warning on hormone replacement therapy (HRT) was added by the FDA in 2002 following the Women’s Health Initiative (WHI) study, which suggested hormone therapy increased the risk of breast cancer, heart disease, and stroke.

The warning caused a dramatic global drop in HRT prescriptions — by some estimates up to 80% — and left millions of menopausal women undertreated for symptoms including hot flashes, sleep disruption, bone loss, cognitive changes, and cardiovascular risk. Subsequent decades of research revealed that the WHI study’s methodology was deeply flawed: participants were older, already at elevated cardiovascular risk, and the findings were broadly misapplied to all women regardless of age or health status.

In February 2026, the FDA removed the black box warning — a significant reassessment of HRT’s risk-benefit profile for menopausal women. Most women, and many clinicians, are still unaware this change occurred.

Early observational data — including a notable study published in The Lancet Obstetrics, Gynaecology & Women’s Health in January 2026 — suggests that women on hormone therapy who also take GLP-1 medications (specifically tirzepatide/Zepbound) may lose up to 35% more weight than women on GLP-1s alone.

Researchers theorize that estrogen may enhance GLP-1’s appetite-suppressing effects. These findings are promising but preliminary — they come from observational studies, not randomized controlled trials. Randomized trials are currently underway.

This is an evolving area of research, and any decisions about combining HRT and GLP-1 therapy should be made in consultation with a qualified healthcare provider.

This is a question for your doctor — and specifically, a doctor who is up to date on the post-2002 evidence base.

The short answer is: the conversation has changed significantly. The removal of the black box warning in February 2026 reflects a major reassessment of HRT’s risk profile. For many women, the benefits of hormone therapy — including protection against bone loss, cardiovascular support, symptom relief, and potentially enhanced response to weight management medications — may outweigh the risks.

The key is individualized assessment. Not every woman is a candidate, but far more women may be than previously thought.

If your doctor is still citing the 2002 WHI study as the primary reason not to pursue HRT, it may be worth seeking a second opinion from a menopause specialist.

The SAVOR Method is a holistic wellness framework developed by Julie Kaminski, MA, NBC-HWC, built around five pillars of sustainable health and happiness:

• Sustenance (nourishing your body intentionally),
• Activity (movement as a daily practice, not punishment),
• Variables (protecting energy, sleep, and hormonal health),
• Organization (structuring your days with purpose), and
• Refuelment (rest, joy, and recovery as non-negotiables).

It is designed specifically for women navigating midlife transitions — including perimenopause, menopause, and post-menopause — who are tired of generic health advice that doesn’t account for their full reality.

The SAVOR Method works independently of any medication and is designed to support lasting change whether or not a woman is using GLP-1s or hormone therapy.

Postmenopausal women are at significantly higher risk for sarcopenia — age-related muscle loss — than younger women or men of the same age.

This matters enormously for weight management because muscle is metabolically active tissue: it burns calories at rest, supports insulin sensitivity, and protects long-term metabolic health.

When women lose weight rapidly — whether through caloric restriction, GLP-1 medications, or both — without prioritizing resistance training and adequate protein intake, a disproportionate amount of that weight loss can come from muscle rather than fat.

The practical upshot: resistance training and protein are not optional add-ons for midlife women. They are the foundation everything else is built on.

One of the most accessible and medically rigorous resources currently available is the Dr. Rachel Rubin, MD episode on The Mel Robbins Podcast (“The Ultimate Guide to Women’s Sexual Health, HRT & Menopause,” March 2026).

Dr. Rubin is a urologist and sexual medicine specialist whose work focuses on closing the research and treatment gap for women’s hormonal health.

The episode covers HRT, sexual health, menopause symptoms, and why so many women have been undertreated for decades. It is two hours and thirteen minutes long. It is worth every minute.